Holen Sie sich die Stockscreener-App
15.26
1.42%
-0.22
Schlusskurs vom Vortag:
$15.48
Offen:
$15.39
24-Stunden-Volumen:
170.17K
Relative Volume:
1.00
Marktkapitalisierung:
$485.04M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-9.60%
1M Leistung:
-31.17%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$14.77
$18.21
52-Wochen-Spanne:
$14.77
$27.99
BlossomHill Therapeutics, Inc. Common Stock Stock (BLSM) Company Profile
Firmenname
BlossomHill Therapeutics, Inc. Common Stock
Sektor
Branche
Telefon
-
Adresse
-
Compare BLSM vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLSM
BlossomHill Therapeutics, Inc. Common Stock
|
15.26 | 485.04M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.46 | 95.60B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.85 | 82.25B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.08 | 53.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.16 | 42.33B | 5.76B | 514.49M | 1.10B | 4.4813 |
BlossomHill Therapeutics, Inc. Common Stock Stock (BLSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-01 | Eingeleitet | Guggenheim | Buy |
| 2026-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-09-01 | Eingeleitet | JP Morgan | Overweight |
BlossomHill Therapeutics, Inc. Common Stock Aktie (BLSM) Neueste Nachrichten
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
Leerink Partners Boosts BlossomHill Therapeutics (NASDAQ:BLSM) Price Target to $40.00 - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Hits New 12-Month HighShould You Buy? - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Announces Earnings Results, Misses Estimates By $7.91 EPS - MarketBeat
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results - Stock Titan
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewswire
BlossomHill Therapeutics (NASDAQ:BLSM) Stock Price Up 5.8%What's Next? - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month HighWhat's Next? - marketbeat.com
BlossomHill stock surges on positive lung cancer trial data By Investing.com - Investing.com South Africa
An experimental lung cancer drug kept disease under control in 88% of 40 patients - Stock Titan
BlossomHill Therapeutics, Inc.'s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM) - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap UpHere's Why - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Upgraded by Guggenheim - marketbeat.com
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Given Average Rating of "Buy" by Brokerages - marketbeat.com
Patients whose lung cancer develops a specific resistance mutation after a targeted drug stops working have no approved pills aimed at it. BlossomHill Therapeutics plans to present updated trial data on Sept. 15. - Stock Titan
BlossomHill (NASDAQ: BLSM) insider buys at $16 and gets options - Stock Titan
OrbiMed adds BlossomHill Therapeutics (BLSM) IPO stake with insider buy - Stock Titan
BlossomHill Therapeutics Insider Bought Shares Worth $5,000,000, According to a Recent SEC Filing - Yahoo Finance
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs - BioSpace
BlossomHill Therapeutics completes IPO and updates governance - TipRanks
BlossomHill Therapeutics shares fall in debut after IPO - Investing.com
BlossomHill Therapeutics Prices Upsized Nasdaq IPO - Yahoo Finance
Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO - Latham & Watkins LLP
BlossomHill Therapeutics Prices Upsized $150 Million Initial Public Offering | BLSM Stock News - Quiver Quantitative
BlossomHill Therapeutics, Inc.BLSMStock Price Today - Zacks Investment Research
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering - GlobeNewswire
BlossomHill Therapeutics (BLSM) director holds $13.59 option to 2036 - Stock Titan
BlossomHill Therapeutics prices $150M IPO at $16 per share - Investing.com
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise - Seeking Alpha
BlossomHill Therapeutics files for Nasdaq IPO at up to $17 per share - Investing.com
BlossomHill Therapeutics files for Nasdaq IPO at up to $17 per share - Investing.com Nigeria
BlossomHill Therapeutics files for Nasdaq IPO under ticker BLSM - Investing.com
BlossomHill Therapeutics, Clinical-Stage Oncology Biotech, Files for Nasdaq Global Select Market IPO - TradingView
BlossomHill Therapeutics prices $150M IPO at $16 per share By Investing.com - Investing.com Nigeria
SGMT Stock Price and Chart — NASDAQ:SGMT - TradingView
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Greenwave Technology Solutions, Inc. Common Stock (GWAV) Historical Quotes - nasdaq.com
PHAT Stock Price and Chart — NASDAQ:PHAT - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
ACRS Stock Price and Chart — NASDAQ:ACRS - TradingView
IRWD Stock Price and Chart — NASDAQ:IRWD - tradingview.com
Finanzdaten der BlossomHill Therapeutics, Inc. Common Stock-Aktie (BLSM)
Es liegen keine Finanzdaten für BlossomHill Therapeutics, Inc. Common Stock (BLSM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
BlossomHill Therapeutics, Inc. Common Stock-Aktie (BLSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 10 '26 |
Buy |
16.00 |
625,000 |
10,000,000 |
2,714,279 |
| Schmid John P. | Director |
Aug 10 '26 |
Buy |
16.00 |
6,000 |
96,000 |
6,000 |
| Chen Bihua | Director |
Aug 10 '26 |
Buy |
16.00 |
312,500 |
5,000,000 |
3,614,034 |
| Keyes Jason A | Chief Financial Officer |
Aug 10 '26 |
Buy |
16.00 |
700 |
11,200 |
700 |
| Liptak Vincent Paul | General Counsel |
Aug 10 '26 |
Buy |
16.00 |
2,200 |
35,200 |
111,412 |
| Liptak Vincent Paul | General Counsel |
Aug 07 '26 |
Buy |
15.80 |
2,500 |
39,500 |
109,212 |
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):